Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Rituximab 13Cyclophosphamide 9Magnetic Resonance Spectroscopy 7Lenalidomide 7venetoclax 6obinutuzumab 5ibrutinib 5Specimen Handling 5fludarabine phosphate 4fludarabine 4Whole-Body Irradiation 4Prednisone 4CT-P10 4Biopsy 4zanubrutinib 3orelabrutinib 3Vincristine 3Mycophenolic Acid 3Cyclosporine 3polatuzumab vedotin 2pirtobrutinib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Doxorubicin 2Busulfan 2Bendamustine Hydrochloride 2voruciclib 1treosulfan 1tafasitamab 1prednylidene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × cc-486 × 90 days × Clear all
NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡